# Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

Source: [nature.com](https://www.nature.com/articles/s41591-026-04716-9) · 2026-11-11 · Medicine
Page: https://themorning.science/story/normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with-dato-76f0c76adf97b3e4
Kind: research · Impact: medium

## In brief

- Researchers developed and validated a computational pathology biomarker, the TROP2 normalized membrane ratio, which quantifies subcellular TROP2 localization.
- The source abstract reports that this ratio predicts improved progression-free survival and other outcomes with datopotamab deruxtecan in non-small-cell lung cancer.
- The study was published online in Nature Medicine on 11 November 2026.

## Why it matters

If validated further, a pathology-based TROP2 membrane measurement could help identify non-small-cell lung cancer patients more likely to benefit from datopotamab deruxtecan.

## Timeline

- 2026-11-11: Published online in Nature Medicine

## Coverage

- [Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer](https://www.nature.com/articles/s41591-026-04716-9) — nature.com, 2026-11-11

Tags: lung cancer, biomarkers, computational pathology, antibody-drug conjugates, trop2

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science